

ELVITEGRAVIR AS ANTIBACTERIAL AGENT

A research group from CIBER, Clinic Hospital - FCRB, Universitat de Barcelona, ISGlobal and IRSICaixa has identified a new therapeutic method related with the use of Elvitegravir against bacterial infections.

The Need

One of the greatest problems which humanity is facing nowadays is the multidrug resistance in bacteria, which is dramatically increasing crisis.

There is a strong need in society to design new therapeutic strategies against multidrug resistant bacterial infections.

The Solution

This new technology provides a new use of an approved antiretroviral for HIV, which has shown effectivity against Gram+ multidrug resistant bacteria.

Innovative Aspects



The main innovate aspect of the method is the alternative use of the already approved antiretroviral Elvitegravir.

Elvitegravir has shown antibacterial activity against a set of clinically relevant multidrug-resistant Gram-positive bacteria including Vancomycin-resistant enterococci and Methicillin-resistant *S. aureus* strains.

No antibacterial activity as such has been shown for any other compound pertaining to the same molecular structural group. This innovative use offers new ways of development for new pharmaceutical treatments.

Stage of Development:

Validated in *in vitro* multidrug resistant bacteria strains.



Intellectual Property:

- Priority European patent application filed.

Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

Contact details